What is a stock summary page? Click here for an overview.
Business Description
Naturewise Biotech & Medicals Corp
NAICS : 325411
SIC : 2833
ISIN : TW0004732003
Description
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 58.59 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.31 | |||||
| Interest Coverage | 92.81 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 10.44 | |||||
| Beneish M-Score | -3.03 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -19.8 | |||||
| 3-Year EBITDA Growth Rate | -34.4 | |||||
| 3-Year EPS without NRI Growth Rate | -46.7 | |||||
| 3-Year FCF Growth Rate | 3.9 | |||||
| 3-Year Book Growth Rate | 1.9 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 10.88 | |||||
| 9-Day RSI | 17.53 | |||||
| 14-Day RSI | 22.84 | |||||
| 3-1 Month Momentum % | -5.17 | |||||
| 6-1 Month Momentum % | 0.27 | |||||
| 12-1 Month Momentum % | 2.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.46 | |||||
| Quick Ratio | 11.07 | |||||
| Cash Ratio | 9.77 | |||||
| Days Inventory | 241.31 | |||||
| Days Sales Outstanding | 39.62 | |||||
| Days Payable | 25.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1 | |||||
| Dividend Payout Ratio | 1.61 | |||||
| Forward Dividend Yield % | 1 | |||||
| 5-Year Yield-on-Cost % | 0.92 | |||||
| Shareholder Yield % | 0.54 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 54.92 | |||||
| Operating Margin % | 3.55 | |||||
| Net Margin % | 7.02 | |||||
| FCF Margin % | 22.36 | |||||
| ROE % | 2.5 | |||||
| ROA % | 2.27 | |||||
| ROIC % | 4.27 | |||||
| 3-Year ROIIC % | -171.15 | |||||
| ROC (Joel Greenblatt) % | 25.72 | |||||
| ROCE % | 2.55 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 64.34 | |||||
| PE Ratio without NRI | 64.34 | |||||
| Price-to-Owner-Earnings | 16.71 | |||||
| PS Ratio | 4.42 | |||||
| PB Ratio | 1.54 | |||||
| Price-to-Tangible-Book | 1.63 | |||||
| Price-to-Free-Cash-Flow | 19.77 | |||||
| Price-to-Operating-Cash-Flow | 19.53 | |||||
| EV-to-EBIT | 30.48 | |||||
| EV-to-EBITDA | 18.43 | |||||
| EV-to-Revenue | 2.23 | |||||
| EV-to-FCF | 9.96 | |||||
| Price-to-GF-Value | 1.28 | |||||
| Price-to-Projected-FCF | 1.5 | |||||
| Price-to-Median-PS-Value | 0.85 | |||||
| Price-to-Graham-Number | 2.16 | |||||
| Price-to-Net-Current-Asset-Value | 1.73 | |||||
| Price-to-Net-Cash | 2.28 | |||||
| Earnings Yield (Greenblatt) % | 3.28 | |||||
| FCF Yield % | 5.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Naturewise Biotech & Medicals Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 224.575 | ||
| EPS (TTM) (NT$) | 0.272 | ||
| Beta | -0.06 | ||
| 3-Year Sharpe Ratio | -0.44 | ||
| 3-Year Sortino Ratio | -0.66 | ||
| Volatility % | 22.16 | ||
| 14-Day RSI | 22.84 | ||
| 14-Day ATR (NT$) | 1.192826 | ||
| 20-Day SMA (NT$) | 21.7725 | ||
| 12-1 Month Momentum % | 2.83 | ||
| 52-Week Range (NT$) | 17.4 - 26.1 | ||
| Shares Outstanding (Mil) | 56.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Naturewise Biotech & Medicals Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Naturewise Biotech & Medicals Corp Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Naturewise Biotech & Medicals Corp Frequently Asked Questions
What is Naturewise Biotech & Medicals Corp(ROCO:4732)'s stock price today?
The current price of ROCO:4732 is NT$17.50. The 52 week high of ROCO:4732 is NT$26.10 and 52 week low is NT$17.40.
When is next earnings date of Naturewise Biotech & Medicals Corp(ROCO:4732)?
The next earnings date of Naturewise Biotech & Medicals Corp(ROCO:4732) is .
Does Naturewise Biotech & Medicals Corp(ROCO:4732) pay dividends? If so, how much?
The Dividend Yield %  of Naturewise Biotech & Medicals Corp(ROCO:4732) is 1% (As of Today), Highest Dividend Payout Ratio of Naturewise Biotech & Medicals Corp(ROCO:4732) was 2.49. The lowest was 0.16. And the median was 0.49. The  Forward Dividend Yield % of Naturewise Biotech & Medicals Corp(ROCO:4732) is 1%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers